UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1789-1796

2008

Volltextzugriff (PDF)

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

Journal of clinical oncology, 2007-05, Vol.25 (15), p.2086-2092

2007

Volltextzugriff (PDF)

Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients

Lung cancer (Amsterdam, Netherlands), 2014-12, Vol.86 (3), p.324-328

2014

Volltextzugriff (PDF)

Human Epidermal Growth Factor Receptor 2 Status and Interval Breast Cancer in a Population-Based Cancer Registry Study

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2362-2368

2012

Volltextzugriff (PDF)

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials

European journal of cancer (1990), 2014-09, Vol.50 (13), p.2211-2218

2014

Volltextzugriff (PDF)

Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

Journal of clinical oncology, 2002-10, Vol.20 (19), p.3947-3955

2002

Volltextzugriff (PDF)

Predictive and Prognostic Significance of Neuron-specific Enolase (NSE) in Non-small Cell Lung Cancer

Anticancer research, 2008-01, Vol.28 (1B), p.507-513

2008

Volltextzugriff (PDF)

Multifactorial Central Nervous System Recurrence Susceptibility in Patients With HER2-Positive Breast Cancer: Epidemiological and Clinical Data From a Population-Based Cancer Registry Study

Cancer, 2011-05, Vol.117 (9), p.1837-1846

2011

Volltextzugriff (PDF)

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

Lung cancer (Amsterdam, Netherlands), 2014-10, Vol.86 (1), p.91-95

2014

Volltextzugriff (PDF)

Activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor‐prognostic untreated diffuse large B‐cell non‐Hodgkin lymphoma

Cancer, 2011-03, Vol.117 (5), p.964-973

2011

Volltextzugriff (PDF)

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.265-271

2014

Volltextzugriff (PDF)

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

Cancer, 2006-12, Vol.107 (12), p.2842-2849

2006

Volltextzugriff (PDF)

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

Lung cancer (Amsterdam, Netherlands), 2012-10, Vol.78 (1), p.92-99

2012

Volltextzugriff (PDF)

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

Lung cancer (Amsterdam, Netherlands), 2010-03, Vol.67 (3), p.355-360

2010

Volltextzugriff (PDF)

Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib

Cancer chemotherapy and pharmacology, 2014-02, Vol.73 (2), p.299-307

2014

Volltextzugriff (PDF)

Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega‐3 fatty acids

British journal of haematology, 2009-04, Vol.145 (1), p.84-86

2009

Volltextzugriff (PDF)

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2003-08, Vol.41 (2), p.227-231

2003

Volltextzugriff (PDF)

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

Lung cancer (Amsterdam, Netherlands), 2009-05, Vol.64 (2), p.199-206

2009

Volltextzugriff (PDF)

Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study

Lung cancer (Amsterdam, Netherlands), 2011-12, Vol.74 (3), p.462-468

2011

Volltextzugriff (PDF)

A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)

Lung cancer (Amsterdam, Netherlands), 2005-10, Vol.50 (1), p.91-96

2005

Volltextzugriff (PDF)

Detection of follicular fluid and serum antibodies by protein microarrays in women undergoing in vitro fertilization treatment

Journal of reproductive immunology, 2011-04, Vol.89 (1), p.62-69

2011

Volltextzugriff (PDF)

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

Journal of clinical oncology, 1996-03, Vol.14 (3), p.814-820

1996

Volltextzugriff (PDF)

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients

Lung cancer (Amsterdam, Netherlands), 2001-02, Vol.31 (2-3), p.303-310

2001

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical Cancer Research

ThemaBiological And Medical Sciences

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Humans
(36)
Medical Sciences
(35)
Aged
(32)
Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Middle Aged
(31)
Oncology
(30)
Adult
(28)
Male
(28)
Tumors
(19)
Lung Neoplasms - Drug Therapy
(18)
Pneumology
(18)
Tumors Of The Respiratory System And Mediastinum
(17)
Treatment Outcome
(15)
Aged, 80 And Over
(14)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(13)
Lung Neoplasms - Pathology
(13)
Pharmacology. Drug Treatments
(12)

13 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

Human Epidermal Growth Factor Receptor 2 Status and Interval Breast Cancer in a Population-Based Cancer Registry Study

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials

Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

Predictive and Prognostic Significance of Neuron-specific Enolase (NSE) in Non-small Cell Lung Cancer

Multifactorial Central Nervous System Recurrence Susceptibility in Patients With HER2-Positive Breast Cancer: Epidemiological and Clinical Data From a Population-Based Cancer Registry Study

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

Activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor‐prognostic untreated diffuse large B‐cell non‐Hodgkin lymphoma

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib

Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega‐3 fatty acids

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study

A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)

Detection of follicular fluid and serum antibodies by protein microarrays in women undergoing in vitro fertilization treatment

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients

Aktive Filter

Suchergebnisse filtern